TuHURA Biosciences (HURA)
NASDAQ:HURA
Want to see HURA full AI Analyst Report?
Top Page
TuHURA Biosciences
(NASDAQ:HURA)
Select Model
Select Model
Rating:52Neutral
Price Target:
$3.00
▲(2.74% Upside)
Action:ReiteratedDate:04/23/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and accelerating cash burn). Technicals are a notable positive with clear momentum above key moving averages, while valuation remains challenged due to ongoing losses and no dividend. Corporate events modestly help via added financing runway but are tempered by higher-cost obligations and Nasdaq listing risk.
Positive Factors
Low reported leverage
Reported debt is modest relative to equity, lowering near-term interest burden and financial risk. A cleaner balance sheet gives management flexibility to prioritize R&D and clinical milestones without immediate debt servicing pressure, supporting program continuity over the next several quarters.
Negative Factors
No revenue and widening losses
The company remains pre-revenue and losses widened materially year-over-year, reflecting increasing spend without commercial offsets. Lack of operating income limits self-funding capacity, heightens dilution risk, and makes strategic progress contingent on external capital over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low reported leverage
Reported debt is modest relative to equity, lowering near-term interest burden and financial risk. A cleaner balance sheet gives management flexibility to prioritize R&D and clinical milestones without immediate debt servicing pressure, supporting program continuity over the next several quarters.
Read all positive factors
TuHURA Biosciences (HURA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$136.28M
Dividend YieldN/A
Average Volume (3M)215.15K
Price to Earnings (P/E)―
Beta (1Y)1.16
Revenue GrowthN/A
EPS Growth95.14%
CountryUS
Employees19
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding63,682,530
10 Day Avg. Volume212,396
30 Day Avg. Volume215,145
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.31
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.29K
Enterprise Value/Ebitda-4.93
Forecast
1Y Price Target
$8.50Price Target Upside191.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TuHURA Biosciences Business Overview & Revenue Model
Company Description
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL....
How the Company Makes Money
null...
TuHURA Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -55.00K | -60.00K | -60.00K |
| EBITDA | -29.36M | -17.43M | -8.27M | -14.74M | -22.62M |
| Net Income | -30.06M | -21.68M | -8.32M | -14.65M | -22.66M |
Balance Sheet | |||||
| Total Assets | 27.35M | 19.97M | 4.36M | 15.20M | 6.40M |
| Cash, Cash Equivalents and Short-Term Investments | 3.62M | 12.66M | 3.67M | 14.25M | 5.55M |
| Total Debt | 502.67K | 202.54K | 2.34M | 138.22K | 644.07K |
| Total Liabilities | 6.42M | 5.37M | 5.92M | 2.89M | 7.15M |
| Stockholders Equity | 20.93M | 14.59M | -1.56M | 12.30M | -747.82K |
Cash Flow | |||||
| Free Cash Flow | -27.71M | -14.79M | -12.03M | -7.54M | -6.57M |
| Operating Cash Flow | -27.63M | -14.73M | -11.95M | -7.51M | -6.56M |
| Investing Cash Flow | -1.34M | -6.05M | -1.30M | -36.28K | -3.28K |
| Financing Cash Flow | 19.93M | 29.77M | 2.66M | 16.25M | 7.04M |
TuHURA Biosciences Technical Analysis
Positive
2.92
Price Trends
1.73
Positive
1.37
Positive
1.95
Positive
Market Momentum
0.34
Negative
70.48
Negative
79.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HURA, the sentiment is Positive. The current price of 2.92 is above the 20-day moving average (MA) of 2.11, above the 50-day MA of 1.73, and above the 200-day MA of 1.95, indicating a bullish trend. The MACD of 0.34 indicates Negative momentum. The RSI at 70.48 is Negative, neither overbought nor oversold. The STOCH value of 79.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HURA.
TuHURA Biosciences Risk Analysis
TuHURA Biosciences disclosed 72 risk factors in its most recent earnings report. TuHURA Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TuHURA Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $107.00M | 4.86 | -243.73% | ― | ― | 60.38% | |
52 Neutral | $136.28M | -1.34 | -179.42% | ― | ― | 95.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $114.37M | -8.98 | -104.27% | ― | ― | 60.12% | |
46 Neutral | $154.36M | -2.62 | -0.04% | ― | 10.37% | 96.92% | |
46 Neutral | $30.56M | -0.51 | -143.59% | ― | ― | -93.71% | |
43 Neutral | $93.41M | 54.17 | -353.36% | ― | -69.99% | 51.48% |
* Healthcare Sector Average
HURA
TuHURA Biosciences
2.14
-1.59
-42.63%
AGEN
Agenus
4.02
1.05
35.35%
INO
Inovio Pharmaceuticals
1.14
-0.57
-33.33%
SKYE
Skye Bioscience
0.87
-0.99
-53.10%
BMEA
Biomea Fusion
1.48
-0.19
-11.38%
CGTX
Cognition Therapeutics
1.28
0.86
204.76%
TuHURA Biosciences Corporate Events
Business Operations and StrategyPrivate Placements and Financing
TuHURA Biosciences Secures $50 Million Credit Facility
Positive
Apr 22, 2026
On April 21, 2026, TuHURA Biosciences, Inc. entered into a secured loan agreement with Parkview Holdings One LLC, an affiliate of its largest shareholder, establishing a revolving credit facility of up to $50 million maturing on April 21, 2031 at ...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresM&A Transactions
TuHURA Biosciences Approves 2025 Executive Compensation Adjustments
Positive
Apr 8, 2026
On April 2, 2026, TuHURA Biosciences’ board compensation committee approved 2025 performance bonuses and 5% cost-of-living salary increases for President and CEO Dr. James Bianco and CFO Dan Dearborn, underscoring the board’s continued...
Delistings and Listing ChangesRegulatory Filings and Compliance
TuHURA Biosciences Receives Nasdaq Minimum Bid Price Notice
Negative
Jan 30, 2026
On January 29, 2026, TuHURA Biosciences disclosed that it had received a notice from Nasdaq stating that its common stock had closed below $1.00 per share for 35 consecutive business days as of January 28, 2026, placing the company out of complian...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.